Philip M. Meyers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Philip M. Meyers has a total of 257 co-authors. Here are the top co-authors by number of shared publications:
Randall T. Higashida
University of California, San Francisco, San Francisco, California
16 shared publicationsH. Christian Schumacher
From the Departments of Radiology (P.M.M.), Neurological Surgery (P.M.M., E.S.C.), Anesthesiology (E.J.H.), Neurology (E.J.H.), and Cardiology (W.A.G.), Columbia University, College of Physicians and Surgeons, New York, NY; Department of Medicine, LeHigh Valley Hospital and Health Network, Allentown, PA (H.C.S.); and Departments of Radiology, Neurology, Neurological Surgery, and Critical Care, University of California San Francisco (R.T.H.).
9 shared publicationsSean D. Lavine
8 shared publications- Colin P. Derdeyn
Department of Radiology, University of Virginia, Charlottesville (C.P.D.).
7 shared publications - Peter Kan
Neurosurgery, The University of Texas Medical Branch at Galveston, Galveston, Texas, USA
7 shared publications David Sacks
6 shared publications
Latest Publications
- 7 May 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 17 (10) , 1078-1082
Five-year results of the SCENT trial with Surpass flow diverters to treat large or giant wide-neck aneurysms
Background One-year and 3-year outcomes for the SCENT trial have previously been reported. However, 5-year (long-term) clinical outcomes have not previously been described. Methods In this multicenter prospective trial, 180 aneurysms in 180 subjects were treated with the Surpass flow diverter system across 26 sites. Patients were followed according to a standardized protocol at 1 month, 6 months, 1 year, 3 years, and 5 years. Aneurysm occlusion, in-stent stenosis, modified Rankin Scale (mRS) scores, and complications were recorded. Results The 5-year clinical follow-up reported 119 subjects and nine deaths with a completion rate of 71.7%, with 5-year angiographic follow-up available in 82 of the surviving 171 patients (48%). Aneurysm occlusion (Raymond Class I) for those patients who underwent angiographic follow-up was 77.8% (91/117) and 90.2% (74/82) at 3 and 5 years. The primary effectiveness composite endpoint was achieved in 80.3% (57/71) of patients. The cumulative proportion of subjects experiencing new or worsening major ipsilateral stroke was 12.8% (23/180) at 36 months, with no new occurrences at 60 months. No late aneurysm ruptures occurred during the 5-year follow-up, and no additional retreatments occurred between 36 and 60 months. Between 3 and 5 years, 52 potential site-reported serious adverse events were sent to CEC for adjudication. Of these, nine were CEC-adjudicated to be serious and four were determined to be related to the procedure/device. Conclusions Five-year findings demonstrate the long-term safety and effectiveness of the Surpass flow diverter for intracranial aneurysm treatment, supported by high occlusion rates and low rates of delayed adverse events in this study. Trial registration number NCT01716117.
- 7 May 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 17 (10) , 1078-1082
Five-year results of the SCENT trial with Surpass flow diverters to treat large or giant wide-neck aneurysms
Background One-year and 3-year outcomes for the SCENT trial have previously been reported. However, 5-year (long-term) clinical outcomes have not previously been described. Methods In this multicenter prospective trial, 180 aneurysms in 180 subjects were treated with the Surpass flow diverter system across 26 sites. Patients were followed according to a standardized protocol at 1 month, 6 months, 1 year, 3 years, and 5 years. Aneurysm occlusion, in-stent stenosis, modified Rankin Scale (mRS) scores, and complications were recorded. Results The 5-year clinical follow-up reported 119 subjects and nine deaths with a completion rate of 71.7%, with 5-year angiographic follow-up available in 82 of the surviving 171 patients (48%). Aneurysm occlusion (Raymond Class I) for those patients who underwent angiographic follow-up was 77.8% (91/117) and 90.2% (74/82) at 3 and 5 years. The primary effectiveness composite endpoint was achieved in 80.3% (57/71) of patients. The cumulative proportion of subjects experiencing new or worsening major ipsilateral stroke was 12.8% (23/180) at 36 months, with no new occurrences at 60 months. No late aneurysm ruptures occurred during the 5-year follow-up, and no additional retreatments occurred between 36 and 60 months. Between 3 and 5 years, 52 potential site-reported serious adverse events were sent to CEC for adjudication. Of these, nine were CEC-adjudicated to be serious and four were determined to be related to the procedure/device. Conclusions Five-year findings demonstrate the long-term safety and effectiveness of the Surpass flow diverter for intracranial aneurysm treatment, supported by high occlusion rates and low rates of delayed adverse events in this study. Trial registration number NCT01716117.
- Open Access
Patient’s age impact on stroke risk and intracranial aneurysm occlusion - SCENT Flow Diverter trial on large and giant aneurysms
Importance: The multicenter, prospective, single-arm, non-randomized SCENT trial on flow diverter (FD) treatment for intracranial aneurysms (IA) was analyzed for patients’ age and IA characteristics impacting stroke and occlusion rates over 5 years. Design: The impact on major ipsilateral stroke and IA occlusion was studied by stratifying age as ≤ 65 years versus >65 years. Product-limit (Kaplan-Meier) estimates of time to both endpoints, stratified by age group, were created. Univariate predictors of time to stroke were identified by including candidate variables in univariable proportional hazards regression models. Those variables found to be significant (p 65 years old. When parent artery stenosis and IA size were entered into a multiple-stepwise survival model, only stenosis remained as an independently significant predictor of time to stroke. At 3-year follow-up, there were a total of 23 strokes (12.8%), with 11 occurring in subjects ≤ 65 years; there was a greater risk for seniors (HR1.96, 95% CI 0.83-4.78). Four patients (4/180; 2.2%) experienced aneurysm rupture within the first week post-treatment, with 3 being ≤ 65 and the fourth aged 66 years. No new strokes were reported between 3 and 5 years. Complete IA occlusion rates for seniors were 60.0% (33/55), 67.6% (25/37), and 85.7% (18/21) at 12, 36, and 60 months, respectively, as compared to 79.1% (87/110), 82.5% (66/80), and 91.8% (56/61) for younger subjects. The time to complete IA occlusion was shorter in younger patients (HR1.53, 95% CI 1.07-2.19). Five subjects (2.8%) underwent retreatment, 2 in 60-year-old patients, and one each aged 64, 70, and 75. Conclusions and Relevance: Age > 65 and parent artery stenosis are related to an increased risk of major ipsilateral stroke in patients with intracranial aneurysms treated with a flow diverter. Age > 65 is also predictive of increased time to and incomplete healing. With demographic shifts, future treatments need to focus on expedited and improved healing. Trial Registration: https://www.clinicaltrials.gov NCT01716117 KEY POINTS: Question: What key variables, including patients’ age and intracranial aneurysm (IA) characteristics, determine procedural stroke risks in subjects treated for large or giant IA with flow-diverting stents? Findings: Aneurysm size and parent artery stenosis impacted occlusion rates and stroke risk, respectively. Over a 5-year observation period, the senior population had a significantly lower occlusion rate and higher risk for stroke, while the younger population was at higher risk for early aneurysm bleed following treatment. Meaning: With demographic shifts and a higher senior population being treated for IA, the stroke risk and incomplete occlusion rates need to be discussed with the patient before treatment.
Open AccessPatient’s age impact on stroke risk and intracranial aneurysm occlusion - SCENT Flow Diverter trial on large and giant aneurysms
Importance: The multicenter, prospective, single-arm, non-randomized SCENT trial on flow diverter (FD) treatment for intracranial aneurysms (IA) was analyzed for patients’ age and IA characteristics impacting stroke and occlusion rates over 5 years. Design: The impact on major ipsilateral stroke and IA occlusion was studied by stratifying age as ≤ 65 years versus >65 years. Product-limit (Kaplan-Meier) estimates of time to both endpoints, stratified by age group, were created. Univariate predictors of time to stroke were identified by including candidate variables in univariable proportional hazards regression models. Those variables found to be significant (p 65 years old. When parent artery stenosis and IA size were entered into a multiple-stepwise survival model, only stenosis remained as an independently significant predictor of time to stroke. At 3-year follow-up, there were a total of 23 strokes (12.8%), with 11 occurring in subjects ≤ 65 years; there was a greater risk for seniors (HR1.96, 95% CI 0.83-4.78). Four patients (4/180; 2.2%) experienced aneurysm rupture within the first week post-treatment, with 3 being ≤ 65 and the fourth aged 66 years. No new strokes were reported between 3 and 5 years. Complete IA occlusion rates for seniors were 60.0% (33/55), 67.6% (25/37), and 85.7% (18/21) at 12, 36, and 60 months, respectively, as compared to 79.1% (87/110), 82.5% (66/80), and 91.8% (56/61) for younger subjects. The time to complete IA occlusion was shorter in younger patients (HR1.53, 95% CI 1.07-2.19). Five subjects (2.8%) underwent retreatment, 2 in 60-year-old patients, and one each aged 64, 70, and 75. Conclusions and Relevance: Age > 65 and parent artery stenosis are related to an increased risk of major ipsilateral stroke in patients with intracranial aneurysms treated with a flow diverter. Age > 65 is also predictive of increased time to and incomplete healing. With demographic shifts, future treatments need to focus on expedited and improved healing. Trial Registration: https://www.clinicaltrials.gov NCT01716117 KEY POINTS: Question: What key variables, including patients’ age and intracranial aneurysm (IA) characteristics, determine procedural stroke risks in subjects treated for large or giant IA with flow-diverting stents? Findings: Aneurysm size and parent artery stenosis impacted occlusion rates and stroke risk, respectively. Over a 5-year observation period, the senior population had a significantly lower occlusion rate and higher risk for stroke, while the younger population was at higher risk for early aneurysm bleed following treatment. Meaning: With demographic shifts and a higher senior population being treated for IA, the stroke risk and incomplete occlusion rates need to be discussed with the patient before treatment.
- Top Cited Papers
- 1 May 2024
- Published by Wolters Kluwer Health in Stroke
- Vol. 55 (5) , 1449-1463
Most Promising Approaches to Improve Brain AVM Management: ARISE I Consensus Recommendations
Brain arteriovenous malformations (bAVMs) are complex, and rare arteriovenous shunts that present with a wide range of signs and symptoms, with intracerebral hemorrhage being the most severe. Despite prior societal position statements, there is no consensus on the management of these lesions. ARISE (Aneurysm/bAVM/cSDH Roundtable Discussion With Industry and Stroke Experts) was convened to discuss evidence-based approaches and enhance our understanding of these complex lesions. ARISE identified the need to develop scales to predict the risk of rupture of bAVMs, and the use of common data elements to perform prospective registries and clinical studies. Additionally, the group underscored the need for comprehensive patient management with specialized centers with expertise in cranial and spinal microsurgery, neurological endovascular surgery, and stereotactic radiosurgery. The collection of prospective multicenter data and gross specimens was deemed essential for improving bAVM characterization, genetic evaluation, and phenotyping. Finally, bAVMs should be managed within a multidisciplinary framework, with clinical studies and research conducted collaboratively across multiple centers, harnessing the collective expertise and centralization of resources.
- 1 May 2024
- Published by Wolters Kluwer Health in Stroke
- Vol. 55 (5) , 1449-1463
Top Cited PapersMost Promising Approaches to Improve Brain AVM Management: ARISE I Consensus Recommendations
Brain arteriovenous malformations (bAVMs) are complex, and rare arteriovenous shunts that present with a wide range of signs and symptoms, with intracerebral hemorrhage being the most severe. Despite prior societal position statements, there is no consensus on the management of these lesions. ARISE (Aneurysm/bAVM/cSDH Roundtable Discussion With Industry and Stroke Experts) was convened to discuss evidence-based approaches and enhance our understanding of these complex lesions. ARISE identified the need to develop scales to predict the risk of rupture of bAVMs, and the use of common data elements to perform prospective registries and clinical studies. Additionally, the group underscored the need for comprehensive patient management with specialized centers with expertise in cranial and spinal microsurgery, neurological endovascular surgery, and stereotactic radiosurgery. The collection of prospective multicenter data and gross specimens was deemed essential for improving bAVM characterization, genetic evaluation, and phenotyping. Finally, bAVMs should be managed within a multidisciplinary framework, with clinical studies and research conducted collaboratively across multiple centers, harnessing the collective expertise and centralization of resources.
- 1 May 2024
- Published by Wolters Kluwer Health in Stroke
- Vol. 55 (5) , 1428-1437
ARISE I Consensus Review on the Management of Intracranial Aneurysms
BACKGROUND: Intracranial aneurysms (IAs) remain a challenging neurological diagnosis associated with significant morbidity and mortality. There is a plethora of microsurgical and endovascular techniques for the treatment of both ruptured and unruptured aneurysms. There is no definitive consensus as to the best treatment option for this cerebrovascular pathology. The Aneurysm, Arteriovenous Malformation, and Chronic Subdural Hematoma Roundtable Discussion With Industry and Stroke Experts discussed best practices and the most promising approaches to improve the management of brain aneurysms. METHODS: A group of experts from academia, industry, and federal regulators convened to discuss updated clinical trials, scientific research on preclinical system models, management options, screening and monitoring, and promising novel device technologies, aiming to improve the outcomes of patients with IA. RESULTS: Aneurysm, Arteriovenous Malformation, and Chronic Subdural Hematoma Roundtable Discussion With Industry and Stroke Experts suggested the incorporation of artificial intelligence to capture sequential aneurysm growth, identify predictors of rupture, and predict the risk of rupture to guide treatment options. The consensus strongly recommended nationwide systemic data collection of unruptured IA radiographic images for the analysis and development of machine learning algorithms for rupture risk. The consensus supported centers of excellence for preclinical multicenter trials in areas such as genetics, cellular composition, and radiogenomics. Optical coherence tomography and magnetic resonance imaging contrast–enhanced 3T vessel wall imaging are promising technologies; however, more data are needed to define their role in IA management. Ruptured aneurysms are best managed at large volume centers, which should include comprehensive patient management with expertise in microsurgery, endovascular surgery, neurology, and neurocritical care. CONCLUSIONS: Clinical and preclinical studies and scientific research on IA should engage high-volume centers and be conducted in multicenter collaborative efforts. The future of IA diagnosis and monitoring could be enhanced by the incorporation of artificial intelligence and national radiographic and biologic registries. A collaborative effort between academic centers, government regulators, and the device industry is paramount for the adequate management of IA and the advancement of the field.
- 1 May 2024
- Published by Wolters Kluwer Health in Stroke
- Vol. 55 (5) , 1428-1437
ARISE I Consensus Review on the Management of Intracranial Aneurysms
BACKGROUND: Intracranial aneurysms (IAs) remain a challenging neurological diagnosis associated with significant morbidity and mortality. There is a plethora of microsurgical and endovascular techniques for the treatment of both ruptured and unruptured aneurysms. There is no definitive consensus as to the best treatment option for this cerebrovascular pathology. The Aneurysm, Arteriovenous Malformation, and Chronic Subdural Hematoma Roundtable Discussion With Industry and Stroke Experts discussed best practices and the most promising approaches to improve the management of brain aneurysms. METHODS: A group of experts from academia, industry, and federal regulators convened to discuss updated clinical trials, scientific research on preclinical system models, management options, screening and monitoring, and promising novel device technologies, aiming to improve the outcomes of patients with IA. RESULTS: Aneurysm, Arteriovenous Malformation, and Chronic Subdural Hematoma Roundtable Discussion With Industry and Stroke Experts suggested the incorporation of artificial intelligence to capture sequential aneurysm growth, identify predictors of rupture, and predict the risk of rupture to guide treatment options. The consensus strongly recommended nationwide systemic data collection of unruptured IA radiographic images for the analysis and development of machine learning algorithms for rupture risk. The consensus supported centers of excellence for preclinical multicenter trials in areas such as genetics, cellular composition, and radiogenomics. Optical coherence tomography and magnetic resonance imaging contrast–enhanced 3T vessel wall imaging are promising technologies; however, more data are needed to define their role in IA management. Ruptured aneurysms are best managed at large volume centers, which should include comprehensive patient management with expertise in microsurgery, endovascular surgery, neurology, and neurocritical care. CONCLUSIONS: Clinical and preclinical studies and scientific research on IA should engage high-volume centers and be conducted in multicenter collaborative efforts. The future of IA diagnosis and monitoring could be enhanced by the incorporation of artificial intelligence and national radiographic and biologic registries. A collaborative effort between academic centers, government regulators, and the device industry is paramount for the adequate management of IA and the advancement of the field.
- Open Access
- 30 July 2023
- Published by BMJ
- Vol. 15 (Suppl 1) , A88.1-A88
E-022 Single-flow diverter stent efficacy of surpass streamline for large and giant extradural ICA aneurysms: comparison of long-term occlusion rates from SCENT and PUFS
Introduction/Purpose Flow diverting stents (FDS) have been established as the primary treatment modality for large and giant extradural ICA aneurysms. The SCENT study, which is the largest prospective FDS study to date, demonstrated the safety and efficacy of the Surpass Streamline™ FDS with the goal of utilizing a single-FDS strategy. We sought to compare both the long-term occlusion rates of extradural ICA aneurysms treated in SCENT and the number of FDS used with the published results of the PUFS (Pipeline) study. Materials and Methods We performed a retrospective subgroup analysis of the prospective multi-center SCENT study dataset. We identified all subjects who had an extradural aneurysm treated and identified the demographics, procedural characteristics, and occlusion rates of those available for 36-month follow-up. These results were compared with the published long-term results of the PUFS study using Fisher’s Exact Test. Results Of the 180 subjects treated in SCENT, 56 had an extradural aneurysm (mean age = 62.9 ± 10.2 years, 94.6% female, 26.8% current smoker). These aneurysms were primarily saccular (48/56, 85.7%) and measured on average 17.4 ± 7.3 mm. Technical success of the index procedure was achieved in 55/56 patients (98.2%). Each SCENT study treatment required on average 1.2 ± 0.5 Surpass FDS as compared to the 105/107 patients treated in PUFS who received multiple devices (mean Pipelines implanted 3, range 1-15). Long-term (36-month) angiographic results from SCENT demonstrated adequate occlusion (Raymond 1 or 2) in 34/35 (97.1%) of aneurysms available for follow-up. This rate of occlusion was nearly identical to the 36-month rate of adequate occlusion from the PUFS study (73/75 aneurysms, 97.3%, p=0.687). Conclusion The Surpass Streamline™ FDS provides comparable long-term efficacy to the Pipeline embolization device for extradural ICA aneurysms with the benefit of a cost-effective single-FDS technique. Disclosures A. Coon: 2; C; Stryker, Medtronic, Microvention, InNeuroCo, Imperative, Rapid, Cerenovus. J. Campos: None. P. Meyers: 2; C; Stryker, Medtronic, Penumbra. P. Kan: 2; C; Stryker, Cerenovus. 4; C; InNeuroCo. P. Taussky: None. A. Wakhloo: 1; C; Philips Medical. 2; C; Stryker, Phenox. 3; C; SCENT Trial. 4; C; InNeuroCo, EpiEP, Neural Analytics, Rist, Analytics 4 Life, ThrombX. R. Hanel: 1; C; NIH, Interline Endowment, Microvention, Stryker, CNX. 2; C; Stryker, Medtronic, Cerenovus, Microvention, Balt, Phenox, Rapid Medical, Q’Apel. 4; C; InNeuroCo, Cerebrotech, eLum, Endostream, Three Rivers Medical Inc., Scientia, RIST, BlinkTBI, Corindus. 6; C; Advisory board for MiVl, Advisory board for eLum, Advisory board for Three Rivers, Advisory board for Shape Medical, Advisory board for Corindus.
- 30 July 2023
- Published by BMJ
- Vol. 15 (Suppl 1) , A88.1-A88
Open AccessE-022 Single-flow diverter stent efficacy of surpass streamline for large and giant extradural ICA aneurysms: comparison of long-term occlusion rates from SCENT and PUFS
Introduction/Purpose Flow diverting stents (FDS) have been established as the primary treatment modality for large and giant extradural ICA aneurysms. The SCENT study, which is the largest prospective FDS study to date, demonstrated the safety and efficacy of the Surpass Streamline™ FDS with the goal of utilizing a single-FDS strategy. We sought to compare both the long-term occlusion rates of extradural ICA aneurysms treated in SCENT and the number of FDS used with the published results of the PUFS (Pipeline) study. Materials and Methods We performed a retrospective subgroup analysis of the prospective multi-center SCENT study dataset. We identified all subjects who had an extradural aneurysm treated and identified the demographics, procedural characteristics, and occlusion rates of those available for 36-month follow-up. These results were compared with the published long-term results of the PUFS study using Fisher’s Exact Test. Results Of the 180 subjects treated in SCENT, 56 had an extradural aneurysm (mean age = 62.9 ± 10.2 years, 94.6% female, 26.8% current smoker). These aneurysms were primarily saccular (48/56, 85.7%) and measured on average 17.4 ± 7.3 mm. Technical success of the index procedure was achieved in 55/56 patients (98.2%). Each SCENT study treatment required on average 1.2 ± 0.5 Surpass FDS as compared to the 105/107 patients treated in PUFS who received multiple devices (mean Pipelines implanted 3, range 1-15). Long-term (36-month) angiographic results from SCENT demonstrated adequate occlusion (Raymond 1 or 2) in 34/35 (97.1%) of aneurysms available for follow-up. This rate of occlusion was nearly identical to the 36-month rate of adequate occlusion from the PUFS study (73/75 aneurysms, 97.3%, p=0.687). Conclusion The Surpass Streamline™ FDS provides comparable long-term efficacy to the Pipeline embolization device for extradural ICA aneurysms with the benefit of a cost-effective single-FDS technique. Disclosures A. Coon: 2; C; Stryker, Medtronic, Microvention, InNeuroCo, Imperative, Rapid, Cerenovus. J. Campos: None. P. Meyers: 2; C; Stryker, Medtronic, Penumbra. P. Kan: 2; C; Stryker, Cerenovus. 4; C; InNeuroCo. P. Taussky: None. A. Wakhloo: 1; C; Philips Medical. 2; C; Stryker, Phenox. 3; C; SCENT Trial. 4; C; InNeuroCo, EpiEP, Neural Analytics, Rist, Analytics 4 Life, ThrombX. R. Hanel: 1; C; NIH, Interline Endowment, Microvention, Stryker, CNX. 2; C; Stryker, Medtronic, Cerenovus, Microvention, Balt, Phenox, Rapid Medical, Q’Apel. 4; C; InNeuroCo, Cerebrotech, eLum, Endostream, Three Rivers Medical Inc., Scientia, RIST, BlinkTBI, Corindus. 6; C; Advisory board for MiVl, Advisory board for eLum, Advisory board for Three Rivers, Advisory board for Shape Medical, Advisory board for Corindus.
- 14 November 2022
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 15 (11) , 1084-1089
Surpass Intracranial Aneurysm Embolization System Pivotal Trial to Treat Large or Giant Wide-Neck Aneurysms – SCENT: 3-year outcomes
Background To report the 3-year safety and effectiveness of the Surpass Streamline flow diverter in the SCENT trial (Surpass Intracranial Aneurysm Embolization System Pivotal Trial to Treat Large or Giant Wide-Neck Aneurysms). Methods The Surpass Streamline flow diverter device was evaluated in a multicenter, prospective, single-arm, non-randomized interventional trial including patients with uncoilable or previously treated but failed aneurysms of the intracranial internal carotid artery. 3-year outcomes were tabulated with descriptive statistics and compared with 1-year outcomes. Results Of 180 patients in the modified intent-to-treat (mITT) cohort, 36-month clinical and angiographic follow-up was available in 134 and 117 cases, respectively. Effectiveness endpoint of complete aneurysm occlusion without clinically significant stenosis or retreatment was met in 71.8% (79/110, 95% CI 62.4% to 80.0%) of cases. Safety composite endpoint was 12.2% (22/180) over the 3-year period, with two major safety events (ipsilateral ischemic strokes) occurring between 12–36 months. Complete aneurysm occlusion was noted in 77.8% (91/117), and 99.1% (116/117) of the patients demonstrated adequate aneurysm occlusion (complete occlusion or neck residual). There were four cases (2.2%) of aneurysm rupture, all occurring within the first month of the index procedure. Target aneurysm retreatment rate was 2.8% (5/180). Conclusion The present findings support the long-term safety and effectiveness of the Surpass Streamline flow diverter device. Trial registration NCT01716117.
- 14 November 2022
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 15 (11) , 1084-1089
Surpass Intracranial Aneurysm Embolization System Pivotal Trial to Treat Large or Giant Wide-Neck Aneurysms – SCENT: 3-year outcomes
Background To report the 3-year safety and effectiveness of the Surpass Streamline flow diverter in the SCENT trial (Surpass Intracranial Aneurysm Embolization System Pivotal Trial to Treat Large or Giant Wide-Neck Aneurysms). Methods The Surpass Streamline flow diverter device was evaluated in a multicenter, prospective, single-arm, non-randomized interventional trial including patients with uncoilable or previously treated but failed aneurysms of the intracranial internal carotid artery. 3-year outcomes were tabulated with descriptive statistics and compared with 1-year outcomes. Results Of 180 patients in the modified intent-to-treat (mITT) cohort, 36-month clinical and angiographic follow-up was available in 134 and 117 cases, respectively. Effectiveness endpoint of complete aneurysm occlusion without clinically significant stenosis or retreatment was met in 71.8% (79/110, 95% CI 62.4% to 80.0%) of cases. Safety composite endpoint was 12.2% (22/180) over the 3-year period, with two major safety events (ipsilateral ischemic strokes) occurring between 12–36 months. Complete aneurysm occlusion was noted in 77.8% (91/117), and 99.1% (116/117) of the patients demonstrated adequate aneurysm occlusion (complete occlusion or neck residual). There were four cases (2.2%) of aneurysm rupture, all occurring within the first month of the index procedure. Target aneurysm retreatment rate was 2.8% (5/180). Conclusion The present findings support the long-term safety and effectiveness of the Surpass Streamline flow diverter device. Trial registration NCT01716117.
- 12 May 2022
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 15 (7) , 679-683
Treatment of large and giant posterior communicating artery aneurysms with the Surpass streamline flow diverter: results from the SCENT trial
Background The Surpass flow diverter was developed to treat intracranial aneurysms not amenable to standard treatment. Indications for use allow placement in the internal carotid artery to the terminus, including the communicating artery segment. Methods The Surpass Intracranial Aneurysm Embolization System Pivotal Trial to Treat Large or Giant Wide Neck Aneurysms (SCENT) trial is an international, multicenter, prospective, non-randomized trial comparing the outcomes of Surpass flow diverter treatment with historic control designed to evaluate the effectiveness and safety of Surpass for the treatment of wide neck (≥4 mm) large or giant intracranial aneurysms ≥10 mm. The primary effectiveness endpoint is the percentage of subjects with 100% aneurysm occlusion without significant stenosis of the parent artery and without retreatment of the target aneurysm at 12 months. The primary safety endpoint is the percentage of subjects experiencing neurologic death or major ipsilateral stroke at 12 months. We report the effectiveness and safety of flow diversion in the subgroup of posterior communicating artery (PComA) aneurysms. Results Of the 180 patients treated, 38 harbored a PComA aneurysm. Mean aneurysm size was 12.2 mm and mean neck width was 4.8 mm. The mean number of Surpass devices used was 1.1 per procedure, with 94.7% of aneurysms treated with one flow diverter. The 12 month primary effectiveness rate was 73.7% (28/38). At 36 months, 68.4% (26/38) of aneurysms remained completely occluded. The 12 month major ipsilateral stroke or neurological death rate was 10.5%. No patients with PComA occlusion after flow diverter placement (54.5%) had clinical sequelae. Conclusions SCENT demonstrated acceptable 12 month effectiveness of flow diversion in PComA aneurysms. Despite associated PComA occlusions in many cases, arterial occlusions were clinically silent. Trial registration number URL: https://www.clinicaltrials.gov. Unique identifier: NCT01716117.
- 12 May 2022
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 15 (7) , 679-683
Treatment of large and giant posterior communicating artery aneurysms with the Surpass streamline flow diverter: results from the SCENT trial
Background The Surpass flow diverter was developed to treat intracranial aneurysms not amenable to standard treatment. Indications for use allow placement in the internal carotid artery to the terminus, including the communicating artery segment. Methods The Surpass Intracranial Aneurysm Embolization System Pivotal Trial to Treat Large or Giant Wide Neck Aneurysms (SCENT) trial is an international, multicenter, prospective, non-randomized trial comparing the outcomes of Surpass flow diverter treatment with historic control designed to evaluate the effectiveness and safety of Surpass for the treatment of wide neck (≥4 mm) large or giant intracranial aneurysms ≥10 mm. The primary effectiveness endpoint is the percentage of subjects with 100% aneurysm occlusion without significant stenosis of the parent artery and without retreatment of the target aneurysm at 12 months. The primary safety endpoint is the percentage of subjects experiencing neurologic death or major ipsilateral stroke at 12 months. We report the effectiveness and safety of flow diversion in the subgroup of posterior communicating artery (PComA) aneurysms. Results Of the 180 patients treated, 38 harbored a PComA aneurysm. Mean aneurysm size was 12.2 mm and mean neck width was 4.8 mm. The mean number of Surpass devices used was 1.1 per procedure, with 94.7% of aneurysms treated with one flow diverter. The 12 month primary effectiveness rate was 73.7% (28/38). At 36 months, 68.4% (26/38) of aneurysms remained completely occluded. The 12 month major ipsilateral stroke or neurological death rate was 10.5%. No patients with PComA occlusion after flow diverter placement (54.5%) had clinical sequelae. Conclusions SCENT demonstrated acceptable 12 month effectiveness of flow diversion in PComA aneurysms. Despite associated PComA occlusions in many cases, arterial occlusions were clinically silent. Trial registration number URL: https://www.clinicaltrials.gov. Unique identifier: NCT01716117.
- 4 February 2021
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 42 (5) , 808-814
A Review of Robotic Interventional Neuroradiology
SUMMARY: Robotic interventional neuroradiology is an emerging field with the potential to enhance patient safety, reduce occupational hazards, and expand systems of care. Endovascular robots allow the operator to precisely control guidewires and catheters from a lead-shielded cockpit located several feet (or potentially hundreds of miles) from the patient. This has opened up the possibility of expanding telestroke networks to patients without access to life-saving procedures such as stroke thrombectomy and cerebral aneurysm occlusion by highly-experienced physicians. The prototype machines, first developed in the early 2000s, have evolved into machines capable of a broad range of techniques, while incorporating newly automated maneuvers and safety algorithms. In recent years, preliminary clinical research has been published demonstrating the safety and feasibility of the technology in cerebral angiography and intracranial intervention. The next step is to conduct larger, multisite, prospective studies to assess generalizability and, ultimately, improve patient outcomes in neurovascular disease.
- 4 February 2021
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 42 (5) , 808-814
A Review of Robotic Interventional Neuroradiology
SUMMARY: Robotic interventional neuroradiology is an emerging field with the potential to enhance patient safety, reduce occupational hazards, and expand systems of care. Endovascular robots allow the operator to precisely control guidewires and catheters from a lead-shielded cockpit located several feet (or potentially hundreds of miles) from the patient. This has opened up the possibility of expanding telestroke networks to patients without access to life-saving procedures such as stroke thrombectomy and cerebral aneurysm occlusion by highly-experienced physicians. The prototype machines, first developed in the early 2000s, have evolved into machines capable of a broad range of techniques, while incorporating newly automated maneuvers and safety algorithms. In recent years, preliminary clinical research has been published demonstrating the safety and feasibility of the technology in cerebral angiography and intracranial intervention. The next step is to conduct larger, multisite, prospective studies to assess generalizability and, ultimately, improve patient outcomes in neurovascular disease.
- 1 February 2021
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 13 (10) , 935-941
Safety of the APOLLO Onyx delivery microcatheter for embolization of brain arteriovenous malformations: results from a prospective post-market study
Background Catheter retention and difficulty in retrieval have been observed during embolization of brain arteriovenous malformations (bAVMs) with the Onyx liquid embolic system (Onyx). The Apollo Onyx delivery microcatheter (Apollo) is a single lumen catheter designed for controlled delivery of Onyx into the neurovasculature, with a detachable distal tip to aid catheter retrieval. This study evaluates the safety of the Apollo for delivery of Onyx during embolization of bAVMs. Methods This was a prospective, non-randomized, single-arm, multicenter, post-market study of patients with a bAVM who underwent Onyx embolization with the Apollo between May 2015 and February 2018. The primary endpoint was any catheter-related adverse event (AE) at 30 days, such as unintentional tip detachment or malfunction with clinical sequelae, or retained catheter. Procedure-related AEs (untoward medical occurrence, disease, injury, or clinical signs) and serious AEs (life threatening illness or injury, permanent physiological impairment, hospitalization, or requiring intervention) were also recorded. Results A total of 112 patients were enrolled (mean age 44.1±17.6 years, 56.3% men), and 201 Apollo devices were used in 142 embolization procedures. The mean Spetzler–Martin grade was 2.38. The primary endpoint was not observed (0/112, 0%). The catheter tip detached during 83 (58.5%) procedures, of which 2 (2.4%) were unintentional and did not result in clinical sequelae. At 30 days, procedure related AEs occurred in 26 (23.2%) patients, and procedure-related serious AEs in 12 (10.7%). At 12 months, there were 3 (2.7%) mortalities, including 2 (1.8%) neurological deaths, none of which were device-related. Conclusion This study demonstrates the safety of Apollo for Onyx embolization of bAVMs. Clinical trial registration CNCT02378883.
- 1 February 2021
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 13 (10) , 935-941
Safety of the APOLLO Onyx delivery microcatheter for embolization of brain arteriovenous malformations: results from a prospective post-market study
Background Catheter retention and difficulty in retrieval have been observed during embolization of brain arteriovenous malformations (bAVMs) with the Onyx liquid embolic system (Onyx). The Apollo Onyx delivery microcatheter (Apollo) is a single lumen catheter designed for controlled delivery of Onyx into the neurovasculature, with a detachable distal tip to aid catheter retrieval. This study evaluates the safety of the Apollo for delivery of Onyx during embolization of bAVMs. Methods This was a prospective, non-randomized, single-arm, multicenter, post-market study of patients with a bAVM who underwent Onyx embolization with the Apollo between May 2015 and February 2018. The primary endpoint was any catheter-related adverse event (AE) at 30 days, such as unintentional tip detachment or malfunction with clinical sequelae, or retained catheter. Procedure-related AEs (untoward medical occurrence, disease, injury, or clinical signs) and serious AEs (life threatening illness or injury, permanent physiological impairment, hospitalization, or requiring intervention) were also recorded. Results A total of 112 patients were enrolled (mean age 44.1±17.6 years, 56.3% men), and 201 Apollo devices were used in 142 embolization procedures. The mean Spetzler–Martin grade was 2.38. The primary endpoint was not observed (0/112, 0%). The catheter tip detached during 83 (58.5%) procedures, of which 2 (2.4%) were unintentional and did not result in clinical sequelae. At 30 days, procedure related AEs occurred in 26 (23.2%) patients, and procedure-related serious AEs in 12 (10.7%). At 12 months, there were 3 (2.7%) mortalities, including 2 (1.8%) neurological deaths, none of which were device-related. Conclusion This study demonstrates the safety of Apollo for Onyx embolization of bAVMs. Clinical trial registration CNCT02378883.
- 22 June 2020
- Published by Wolters Kluwer Health in Operative Neurosurgery
- Vol. 19 (5) , E471-E472
Commentary: Access Through the Anatomical Snuffbox for Neuroendovascular Procedures: A Single Institution Series
In “Access through the anatomical snuffbox for neuroendovascular procedures: a single center series,” the authors demonstrate the safety and feasibility of cerebral vascular procedures using radial arterial access via the anatomical snuffbox.1 In a series of 120 patients, the majority (92.5%) of cases are diagnostic; technical success (100%) is excellent; and the complications (1.67%) are minor, not neurological, and without sequelae. Moreover, both mean fluoroscopic time (10.8 min) and mean radiation exposure (27,672.2 mGycm2) are comparable to prior reports.2 Yet, the authors are selective in their application of transradial access technique: mean number of vessels catheterized is 2.5 (range 1-6) and therapeutic procedures limited (7.5% of selected cases).
- 22 June 2020
- Published by Wolters Kluwer Health in Operative Neurosurgery
- Vol. 19 (5) , E471-E472
Commentary: Access Through the Anatomical Snuffbox for Neuroendovascular Procedures: A Single Institution Series
In “Access through the anatomical snuffbox for neuroendovascular procedures: a single center series,” the authors demonstrate the safety and feasibility of cerebral vascular procedures using radial arterial access via the anatomical snuffbox.1 In a series of 120 patients, the majority (92.5%) of cases are diagnostic; technical success (100%) is excellent; and the complications (1.67%) are minor, not neurological, and without sequelae. Moreover, both mean fluoroscopic time (10.8 min) and mean radiation exposure (27,672.2 mGycm2) are comparable to prior reports.2 Yet, the authors are selective in their application of transradial access technique: mean number of vessels catheterized is 2.5 (range 1-6) and therapeutic procedures limited (7.5% of selected cases).